By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ALSERES Pharmaceuticals, Inc. 

85 Main Street

Hopkinton  Massachusetts  01748  U.S.A.
Phone: 508-497-2360 Fax: 508-497-9964


SEARCH JOBS



Segment
Pharmaceuticals





Company News
ALSERES Pharmaceuticals, Inc. (ALSE) Reports License of Altropane┬« Worldwide Rights to Navidea Biopharmaceuticals (NEOP) 8/1/2012 7:40:28 AM
Delisting of Securities of ALSERES Pharmaceuticals, Inc. (ALSE) From The NASDAQ Stock Market 7/17/2009 8:51:38 AM
ALSERES Pharmaceuticals, Inc. (ALSE) Shares Begin Trading on the Pink Sheets OTC Market 5/8/2009 11:29:21 AM
ALSERES Pharmaceuticals, Inc. (ALSE) and BioAxone Therapeutic Inc. Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology 4/30/2009 10:46:19 AM
ALSERES Pharmaceuticals, Inc. (ALSE) Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements 4/14/2009 12:26:12 PM
ALSERES Pharmaceuticals, Inc. (ALSE) Receives Special Protocol Assessment Agreement from FDA for Phase III Trial of Altropane 4/7/2009 8:19:52 AM
ALSERES Pharmaceuticals, Inc. (ALSE) Complies with NASDAQ Rule Regarding Recently Filed 10-K 3/31/2009 11:33:13 PM
ALSERES Pharmaceuticals, Inc. (ALSE) Reports 2008 Results 3/26/2009 11:24:09 AM
ALSERES Pharmaceuticals, Inc. (ALSE) Announces $200,000 Financing 2/27/2009 9:41:47 AM
ALSERES Pharmaceuticals, Inc. (ALSE) Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program 2/3/2009 1:20:06 PM
12345
//-->